Related references
Note: Only part of the references are listed.The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents
Sung-Han Hsiao et al.
CANCER LETTERS (2019)
Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Kshitij Verma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
Ning Ji et al.
FRONTIERS IN ONCOLOGY (2019)
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
K. Reiter et al.
LEUKEMIA (2018)
Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile
Eva Novotna et al.
ARCHIVES OF TOXICOLOGY (2018)
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
Shaocong Wu et al.
MOLECULAR CANCER (2018)
Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment
Eva Novotna et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robert W. Robey et al.
NATURE REVIEWS CANCER (2018)
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis
Richard M. Stone et al.
BLOOD ADVANCES (2018)
Midostaurin for the treatment of acute myeloid leukemia
Mrinal M. Patnaik
FUTURE ONCOLOGY (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia
Lindsay C. Stansfield et al.
PHARMACOTHERAPY (2017)
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia
Marlise R. Luskin et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis
Sabine Kayser et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Aldo-Keto Reductase AKR1C1-AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy
Chen-Ming Zeng et al.
FRONTIERS IN PHARMACOLOGY (2017)
Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines
Kshitij Verma et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro
Daniela Cihalova et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Derek W. Edwardson et al.
CURRENT DRUG METABOLISM (2015)
Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells
Toshiyuki Matsunaga et al.
ANTI-CANCER DRUGS (2014)
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate
F. Khanim et al.
BRITISH JOURNAL OF CANCER (2014)
Carbonyl reduction pathways in drug metabolism
Petra Malatkova et al.
DRUG METABOLISM REVIEWS (2014)
Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3
Jakub Hofman et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2014)
Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro
Lucie Skarydova et al.
XENOBIOTICA (2013)
A Correlation between Cytotoxicity and Reductase-Mediated Metabolism in Cell Lines Treated with Doxorubicin and Daunorubicin
Onkar S. Bains et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization
Allan D. Heibein et al.
BMC CANCER (2012)
Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily
Lucie Skarydova et al.
DRUG METABOLISM REVIEWS (2012)
Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia
Savitha Varatharajan et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Reversing multidrug resistance by tyrosine kinase inhibitors
Miao He et al.
CHINESE JOURNAL OF CANCER (2012)
ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients
Christophe Marzac et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progressioan
Mikhail G. Dozmorov et al.
BMC CANCER (2010)
Naturally Occurring Variants of Human Aldo-Keto Reductases with Reduced In Vitro Metabolism of Daunorubicin and Doxorubicin
Onkar S. Bains et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer
Michael C. Byrns et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2010)
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids
Lucie Skarydova et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2009)
Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dΔ12,14,PGJ2
R. E. Hayden et al.
LEUKEMIA (2009)
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis
Lane Birtwistle et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2009)
MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia
Maria M. Ho et al.
EXPERIMENTAL HEMATOLOGY (2008)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis et al.
BLOOD (2006)
α,β-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor
T Shiraki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Biochemical mechanisms of drug action: what does it take for success?
DC Swinney
NATURE REVIEWS DRUG DISCOVERY (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C
DJ Propper et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
